Welcome to our dedicated page for Charlottes Web news (Ticker: CWBHF), a resource for investors and traders seeking the latest updates and insights on Charlottes Web stock.
Charlotte's Web Holdings, Inc. reports developments around its hemp-derived botanical wellness business, including operating results, cost structure updates, product-channel activity, and federal policy affecting CBD and full-spectrum hemp products. The company describes itself as a Certified B Corporation focused on hemp extract wellness, with categories that include CBD tinctures, gummies, capsules, topical creams and lotions, hemp-derived THC microdose gummies, functional mushroom gummies, and CBD pet products.
Recurring updates also cover regulatory and healthcare-access initiatives for eligible hemp products, distribution through retailers, healthcare practitioners, and online channels, and its exposure to cannabinoid pharmaceutical development through DeFloria. News frequently links these themes to product quality controls, vertically integrated operations, shareholder matters, and capital-structure or governance developments.
Charlotte's Web (OTCQX:CWBHF) reported Q1 2026 results and outlined a proposed balance sheet recapitalization with BAT. The transaction would convert about $54 million of debentures, add $10 million in equity, cut roughly $3 million in annual interest and leave BAT with about 40% ownership.
Q1 2026 revenue was $11.2 million (down 9% year over year) with gross margin of 46.6%. Net loss was $13.1 million (including an $8.9 million non-cash fair value charge), while Adjusted EBITDA improved to a loss of $1.7 million from $2.8 million. SG&A fell 17.7% to $9.5 million and cash was $5.2 million on March 31, 2026.
The company highlighted the April 1 CMS BEI pathway for eligible hemp-derived CBD products, ongoing internalization of gummy manufacturing, an upgrade to the OTCQX Best Market, and plans to initiate the Phase 2 trial of DeFloria’s AJA001 for ASD irritability in mid-2026.
Charlotte's Web (BTI) reported Q4 2025 and full-year results and disclosed a material strategic transaction with British American Tobacco (BAT) and participation in the CMMI Medicare pilot.
Highlights: FY revenue $49.9M, FY gross profit $21.7M (43.5%), Q4 revenue $13.3M, Q4 net loss $11.5M. BAT transaction would convert C$75.3M debenture, add US$10M equity, and leave BAT with ~40% ownership pending approvals.
Charlotte's Web (OTCQB: CWBHF / TSX: CWEB) announced a transaction with BAT (British American Tobacco) to convert C$75.3M principal plus C$14.2M accrued interest into equity at C$0.94 and for BAT to invest an additional US$10M via private placement.
The deal issues ~110M shares to BAT, eliminates ~US$65M debt, stops future interest accrual, and would leave BAT with ~40.8% ownership subject to shareholder and TSX approvals.
Charlotte's Web (OTC: CWBHF) will release its 2025 fourth quarter and full year financial results before market open on March 31, 2026. A conference call to review results is scheduled the same day at 11:00 A.M. ET, with multiple participation options and a replay available through April 7, 2026.
The company said the call will include a live webcast and an extended replay on the investor relations website; registration and dial‑in details are provided for investors and analysts.
Charlotte's Web (OTCQB: CWBHF) welcomed new CMS guidance announced March 2026 that creates structured access to eligible full‑spectrum hemp products through CMS Innovation Center models. CMS's BEI guidance defines eligible orally administered hemp products as containing up to 3 mg THC per serving, enabling non‑intoxicating full‑spectrum CBD options in clinical conversations.
The company says the framework supports patient‑provider discussions, emphasizes consumer safety and product quality, and aligns with Charlotte's Web's mission to advance safe, science‑backed hemp wellness products.
Charlotte's Web (OTC: CWBHF) praised Representative Morgan Griffith for leading the introduction of the HEMP Act, a federal hemp bill described as establishing FDA oversight, manufacturing standards, and consumer safety requirements while preserving lawful access to compliant CBD products. The company said the framework aims to target unsafe and illicit products while protecting responsible, lawfully sold hemp-derived cannabinoids used by patients, veterans, and other consumers.
Charlotte's Web also thanked patient advocates and Coalition for Access Now for uniting stakeholders behind a science-based hemp marketplace.
DeFloria (OTCQB:CWBHF) says a Presidential Executive Order reclassifying cannabis to Schedule III accelerates its FDA botanical drug program for autism-related irritability. DeFloria reports a cleared botanical IND, a Study May Proceed letter, a completed Phase 1 PK/PD trial showing safety and tolerability, and FDA authorization to start a Phase 2 program for AJA001 oral solution. The company positions these milestones and standardized pharmaceutical-grade formulation as catalysts for research funding, academic trials, institutional investment, and pharma partnerships after rescheduling on Dec 19, 2025.
Charlotte's Web (OTCQB: CWBHF) will serve as a CBD provider in a landmark CMMI Medicare and Medicaid pilot announced Dec 18, 2025, enabling reimbursement for science-backed CBD for senior oncology patients.
The company plans to offer selected products early 2026 via a secure online healthcare portal that combines eCommerce with advanced data security. The pilot pairs Realm of Caring for patient support and the company's Scientific Advisory Board for clinical guidance, and targets improved affordability for seniors within a population of 67 million Medicare beneficiaries.
ONE HEMP (CWBHF) warns that language in the Agriculture, Rural Development, and FDA Appropriations Act would effectively ban many full-spectrum CBD products by imposing a 0.4 mg total THC per container limit, which the group calls unscientific and harmful to consumer access. ONE HEMP cites peer-reviewed research (Dr. Ryan Vandrey) and industry experts (Dr. Marcel Bonn-Miller) to argue that oral THC up to 2.8 mg shows no subjective impairment and that trace THC supports a full-spectrum "entourage effect."
The bill includes a one-year implementation window; House and Senate lawmakers are preparing parallel legislative responses to establish manufacturing, labeling, synthetic cannabinoid prohibitions, and youth safeguards. ONE HEMP is mobilizing stakeholders to seek balanced, science-based regulation that preserves consumer access and public health.
Charlotte's Web (OTC:CWBHF) reported Q3 2025 results on Nov 12, 2025: consolidated revenue of $11.5M (down 8.6% YoY), gross profit of $4.5M (38.9% margin), and net loss of $5.8M or $(0.04) per share. Adjusted EBITDA improved to $(2.1)M from $(3.9)M a year ago.
Operational highlights include full internalization of Brightside gummy manufacturing, a Scientific Advisory Board launch, a B2B channel restructuring with a $0.5M chargeback reserve, and FDA clearance for DeFloria Phase 2 IND for ASD irritability. Cash was $9.8M and total assets $81.6M as of Sept 30, 2025.